Iohexol
 | |
| Clinical data | |
|---|---|
| Trade names | Omnipaque, Hexopaque, Oraltag, others |
| Other names | 5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intrathecal, intravascular, by mouth, intracavital, rectal |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | Low |
| Metabolism | Nil |
| Elimination half-life | Variable |
| Excretion | Kidney, unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.060.130 |
| Chemical and physical data | |
| Formula | C19H26I3N3O9 |
| Molar mass | 821.142 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 174 to 180 °C (345 to 356 °F) |
| |
| |
  (what is this?) (verify) | |
Iohexol, sold under the trade name Omnipaque among others, is a contrast agent used for X-ray imaging.[4] This includes when visualizing arteries, veins, ventricles of the brain, the urinary system, and joints, as well as during computed tomography (CT scan).[4] It is given by mouth, injection into a vein, or into a body cavity.[5]
Side effects include vomiting, skin flushing, headache, itchiness, kidney problems, and low blood pressure.[4] Less commonly allergic reactions or seizures may occur.[4] Allergies to povidone-iodine or shellfish do not affect the risk of side effects more than other allergies.[6] Use in the later part of pregnancy may cause hypothyroidism in the baby.[7] Iohexol is an iodinated non-ionic radiocontrast agent.[4] It is in the low osmolar family.[8]
Iohexol was approved for medical use in 1985.[9] It is on the World Health Organization's List of Essential Medicines.[10][5]
Chemistry
[edit]The osmolality of iohexol ranges from 322 mOsm/kg—approximately 1.1 times that of blood plasma—to 844 mOsm/kg, almost three times that of blood.[11] Despite this difference, iohexol is still considered a low-osmolality contrast agent; the osmolality of older agents, such as diatrizoate, may be more than twice as high.[12]
Adverse effects
[edit]The most common side effects after intravenous injections are: pain at the site of injection (3%), blurring of vision (2%), nausea (2%), arrhythmia (2%), taste perversion (1%), hypotension (0.7%), and vomiting (0.7%).[13]
Society and culture
[edit]Naming
[edit]It is sold under the brand names Omnipaque.[14] It is also sold as a density gradient medium under the names Accudenz, Histodenz, and Nycodenz.[15][16]
Available forms
[edit]It is available in various concentrations, from 140[13] to 350[17] milligrams of iodine per milliliter.[13] Iohexol can given as intrathecal, intravascular, oral, rectal, intraarticular, or into the body cavity.[13]
References
[edit]- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
- ^ "Regulatory Decision Summary for Omnipaque". Drug and Health Products Portal. 29 December 2023. Retrieved 2 April 2024.
- ^ a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 317–8. hdl:10665/44053. ISBN 9789241547659.
- ^ a b Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 171. ISBN 9781284057560.
- ^ ACR Manual on Contrast Media v10.3. 2017 (PDF). American College of Radiology. 2017. p. 6. ISBN 9781559030120. Archived (PDF) from the original on 1 January 2018. Retrieved 1 January 2018.
- ^ Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. p. 761. ISBN 9781608317080. Archived from the original on 1 January 2017.
- ^ Sutton D, Young JW (2012). A Short Textbook of Clinical Imaging. Springer Science & Business Media. p. 235. ISBN 9781447117551. Archived from the original on 1 January 2017.
- ^ Broe ME, Porter GA, Bennett WM, Verpooten GA (2013). Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals. Springer Science & Business Media. p. 325. ISBN 9789401590884. Archived from the original on 1 January 2017.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ GE Healthcare (May 2006). "Omnipaque (Iohexol) injection. Product label". DailyMed. U.S. National Library of Medicine. Retrieved 28 March 2007.
- ^ Amersham Health (April 2006). "Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label". DailyMed. U.S. National Library of Medicine. Archived from the original on 23 May 2011. Retrieved 29 March 2007.
- ^ a b c d "Highlights of prescribing information for Omnipaque" (PDF). US Food and Drug Administration. Archived from the original (PDF) on 11 July 2022. Retrieved 13 December 2022.
- ^ "Omnipaque" (PDF). Ireland: Health Products Regulatory Authority. January 2018. Retrieved 31 July 2020.
- ^ "HistoDenz" (PDF). Product information sheet. Sigma-Aldrich. D2158. Archived from the original (PDF) on 20 November 2015. Retrieved 19 November 2015.
- ^ "Nycodenz®: A universal density gradient medium" (PDF). Axis-Shield Density Gradient Media. Archived from the original (PDF) on 26 February 2015. Retrieved 19 November 2015.
- ^ Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Omnipaque 350 mg J/ml Infusionsflasche.
